What Happened?
San Diego, CA-based Crinetics Appointed Stacey Harte as Vice President, Global Product Lead
Date of management change: April 30, 2022
San Diego, CA-based Crinetics Appointed Stacey Harte as Vice President, Global Product Lead
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.
Stacey Harte is Vice President, Global Product Lead at Crinetics. Previously, Stacey held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Mancini Raoul, Ghaderi Raouf, Weber Kurt, Sanford Diane, Carroll John, Ordonez Beatrice, Fagel Jeff, DiPietro Carol, Jansen Roger, Davis Jim, Stoner Matthew
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.